JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S6

# Advancements in Molecular Diagnostics for Early Disease Detection

**[1] Faisal Khalaf Khashan Alshammri, [2]. Ahmad Abdulaziz Al Asaf, [3]. Abdullah Ramadan Alanazi, [4]. Khallad Shayee Naseer Algabbaa, [5]. Saud Mahal ALrakheess, [6]. Nasser Saud Nasser AlShammari, [7]. Talal Obaid Almuhayhi, [8]. Abdalsalam O. Almuhihi, [9]. Adel Saleh Awad AlRashedi, [10]. Ahmad Nazzal Gareeb Alenazy.**

1. *Laboratory Technician, Ministry of Health, Hail*
2. *Laboratory, Central Blood Bank, Hail*
3. *Laboratory Specialist, Central Blood Bank, Hail*
4. *Laboratory Technician, Central Blood Bank, Hail*
5. *Laboratory, King Khaled Hospital, Hail*
6. *Laboratory, Central Blood Bank, Hail*
7. *Laboratory Specialist, Hail General Hospital, Hail*
8. *Laboratory Technician, Hail Health Cluster, Hail*
9. *Laboratory Specialist, Central Blood Bank, Hail*
10. *Laboratory Technician, Maternity and Children's Hospital, Hail*

**Abstract**
The development of molecular diagnostics for personalized and evidence-based medicine has been a major driving force in medical research over recent decades. Due to technological advances in areas such as robotics, genetics, and bioinformatics, and thanks to reduced reagent costs, commercial tools for the detection of a myriad of diseases on the basis of thousands of genetic markers are now within our grasp. Coupled with the discovery of disease-specific biomarkers, they pave the way for non-invasive, early detection in a clinical diagnostic setting. Rapid advancements in microfluidics and digital plasmonics also play a role in the development of robust diagnostic instruments for rapid point-of-care diagnostic testing at the bedside. In this review, we aim to provide an overview of recent developments in the preclinical stages of molecular diagnosis that use blood-derived analytes such as circulating DNA, exosomes, and microRNAs or circulating DNA from other body fluids such as urine or cerebrospinal fluid. We also emphasize the importance and advantages of combining different types of markers to improve the accuracy of diagnostic tests.
**keywords:**
Early disease detection, cancers,Molecular Diagnostics ‹Disease Detection

## 1. Introduction

Early disease detection is of utmost importance when it comes to providing appropriate therapeutic, surgical, and management choices. These choices not only improve the success rate of outcomes but also have a significant impact on the disease itself. The latest advancements in molecular diagnostics have the potential to revolutionize the way we approach illnesses by enabling early-stage disease monitoring. Efforts to detect cancer, in particular, have primarily focused on identifying circulating tumor cells before they have a chance to locally spread and cause symptoms. However, with the advancements in molecular genetics, it is now possible to isolate, sequence, and detect even the smallest lesions with less invasive methods and without any theoretical constraints. (Sethi et al.2024) In this context, it is crucial to explore the latest developments in molecular diagnostics that involve protein biomarkers. These biomarkers serve as indicators of specific diseases and can be used in diagnosis and monitoring. Additionally, novel ion microarray methods have shown promising results in identifying genetic changes that could be early signs of diseases. These methods allow for more in-depth analysis of nucleic acids, which can further aid in the detection and monitoring of diseases.

(Addissouky et al., 2024) Circulating nucleic acid analyses have also emerged as a valuable tool in molecular diagnostics. These analyses involve the study of nucleic acids, such as DNA and RNA, that are found circulating in the blood or other bodily fluids. By analyzing these nucleic acids, scientists can gain insights into the presence of certain diseases and monitor disease progression. (Johnson et al.2022) As promising as these advancements in molecular diagnostics are, it is important to address the technical challenges that still need to be overcome. Issues such as sensitivity, specificity, and standardization need to be addressed to ensure the accuracy and reliability of these diagnostic methods. Additionally, the current diagnostic landscape should be considered to identify the areas where clinical molecular diagnostics can have the greatest impact. In conclusion, early disease detection through molecular diagnostics has the potential to transform the field of medicine. The exploration of protein biomarkers, novel ion microarray methods, and circulating nucleic acid analyses offer exciting prospects for improving disease detection and monitoring. It is essential to continue addressing the technical challenges and refining these methods to realize their full potential in clinical practice. (Islam and Iqbal, 2020)

## 2. Fundamentals of Molecular Diagnostics

Molecular diagnostics allows for the development of tests at the patient level while leveraging the etiologic understanding of diseases. Desirable attributes of molecular diagnostics include a measurable biological substrate that informs about the disease and is a direct target not subject to biological canalization, facilitating earlier detection of the disease. Testing DNA or RNA via a biopsy poses more immediate ethical considerations as compared to other tissue types. There are a number of key issues that must be addressed to facilitate the use of molecular diagnostics for early disease detection. These issues include a broad imperative to move away from disease-centered diagnostics to person-centered diagnostics, obstacles for personalized medicine, and stakeholder biases. Ethical issues include the conflation of research and diagnostic use and consent issues as patients may not be informed about the collection of their samples and the testing methods used. (Lopes et al., 2022)

The clinical applications of molecular diagnostics require that disparate technologies converge. Tumor profiling at the molecular level may lead to better patient treatment. This treatment is not just relevant in the tailoring of therapeutic strategies toward the patients but is also part of the strategy designed to manage risk. The diagnostic and therapeutic power of molecular diagnostics may lead to observable shifts in the healthcare system. The use of molecular diagnostics will be plagued by some hurdles. Ethical issues related to the collection of samples or use of genetic and genomic information include the dichotomy of tissue-specific informed consent versus blanket consent. The third issue is the disease status and diagnostic and therapeutic options. Early disease detection shifts the diagnosis and treatment from the hospital and clinic to the retail industry while genetic discrimination is also a concern. Clients perform tests and biopsies as part of their daily routine. Facilitated access to molecular diagnostic data encourages behavior that improves the relationship between a person and their body and has implications for health resource utilization. Data query issues become a huge concern for the entire field of molecular diagnostics resulting from the tensions that are created. Ethical issues mainly focus on the right of healing and the rights of the young and the old in the healthcare dispensation. A comprehensive medical privacy policy is necessary to address these issues to ensure the development and wide availability of molecular diagnostics. (Ren et al.2024)

### 2.1. Principles and Techniques

The main drive to use molecular diagnostics to detect or diagnose a disease is that, with increasing knowledge of disease causation, the treatments of the future will contain an increasingly early intervention in disease causation. The clinical advantage of molecular diagnostics for rare diseases is that it allows an early diagnosis. This could lead to intervention at an earlier stage of disease progression, when treatments could potentially be more effective

or to pre-symptomatic detection of a disease, which could enable more timely treatments. Thereby, the disease progression could possibly be delayed or mitigated to such an extent that its overall impact is reduced. However, making this clinical promise a reality requires good coverage of the spectrum of genetic variation. (Groft et al., 2021)

In a clinical setting, molecular diagnostics is increasingly centered on technologies for analyzing nucleic acids. Several molecular diagnostic analyses are now approved with increasing assay success rates. The other major disease area for molecular diagnostics is cancer. The main types of samples being tested are solid tissue or body fluids derived from the body's various cavities. However, the development of molecular diagnostic tests is progressing at a less advanced state compared to hereditary diseases. High-quality genetic information mediates the development of invaluable medical actions such as molecularly targeted drugs, the existence of diagnostic assays employed for clinical choice, and advancing essential tools for patients to realize their genetic information. (Kang et al., 2022)

## 3. Applications in Early Disease Detection

The goal of early disease detection is to use powerful tools of molecular diagnostics to detect a potential health problem early enough to either prevent its progression or provide more timely and effective treatment before irreversible damage occurs. It ultimately provides a primer for personalized medicine, serving as the bedrock for a range of tools for medicine tailored to specific individual patients. We discuss applications in molecular diagnostics for early disease detection, use challenges where one size does not fit all, and sampling. Some discussion in this section is of more forward-looking components to reflect an evolving and potentially disruptive field. Many of the technologies examined are largely relevant today – we saw tools such as dipstick tests allowing patients to monitor disease years after PCR was proposed. (Udugama et al.2020)

Molecular diagnostics is defined here as a suite of technologies designed to perform the process of identifying and characterizing a pathogen or a genetic or protein marker with extremely high specificity and sensitivity. Such markers are biomolecules that can be detected using defined assays, and their presence or absence or quantification gives information about a patient's health state. The broad field of molecular diagnostics can be narrowed further based on its role in health through detection and treatment strategies. Early detection is a term that describes how effective use of molecular diagnostics can improve patient health and control health care costs. It is an approach that attempts to identify a patient's disorder as early as possible, typically by detecting a potential health problem before symptoms become apparent and irreversible damage to the body occurs. (MacLean et al.2020)

### 3.1. Cancer

This leads to a critical next question: how does one build a disease model and then validate predictions in an appropriate human system, choosing minimally invasive strategies and having a practical and realistic plan for broad-based application of validated diagnostics into the health care system? The scientific approach will increasingly build on a set of already important but rapidly advancing technologies in molecular diagnostics. These new approaches bring the potential benefits of early disease detection and treatment to reality. Measurement and understanding of networks of populations of proteins or genes and their subsequent patterns in urine, blood, or sputum can achieve these challenging goals. Ongoing and proposed studies of new, minimally invasive diagnostic approaches using linked systems of studies, including biosampling early at baseline, provide an increasing number of important examples in diseases affecting most Americans. (Crosby et al.2022)

The molecular diagnostics focus on four major areas: proteomics to measure a set of proteins using mass spectrometry and immunoassay; genomics to use sequence analysis and genotyping to measure a set of genes and miRNA and/or cytosine modification to measure gene regulation and control as patterns of miRNA or cytosine modification in specific cell types; blood

transcriptome to measure a set of genes using molecular classifiers and blood; and urine and induced sputum as noninvasive tissue-based biowindows and clinical samples. More than 90% of prostate cancer deaths, 20% of female breast cancer deaths, and many additional deaths from other cancers in Americans result from progression to having a 'critical biomarker' that is detected years to months after local or regional treatment is possible. MBI has a transdisciplinary goal to speed development, improve access, and reduce costs of personalized history-based medicine using appropriate use of noninvasive molecular diagnostics for early disease detection. (Tonry et al., 2020)

### 3.2. Infectious Diseases

The use of molecular diagnostics for pathogen detection and epidemiologic and evolutionary studies is commonplace in the field of infectious diseases and largely drives innovation in this area. As a result, these technologies are continually becoming more robust. Many multiplex microarrays are available for the detection of specific pathogens, with these platforms having an increased ability to detect new or unexpected emerging diseases. Advances in next-generation sequencing have already facilitated the discovery of many new viruses, bacteria, and fungi. Their speed and sensitivity hold promise for the diagnosis of febrile illnesses and outbreaks of unknown aetiology. For these reasons, next-generation sequencing could be incorporated into the routine clinical diagnosis of many infectious diseases in the near future. Sequencing has also been used to characterize outbreaks and hospital pathogen reservoirs. The long read lengths of the new third-generation sequencing technology will enable complete bacterial and viroid genomes and pathogen gene clusters to be fully sequenced and fully characterized for epidemiologic comparison for population genetics studies, thus replacing previous methods. (Tsang et al., 2021)

## 4. Challenges and Limitations

Challenges and limitations of molecular diagnostics must always be kept in mind. Foremost is the need for a comprehensive understanding of pathogenesis and the timely discovery and validation of adequate biomarkers. Next is the critical validity of the technical assay. This requires reliable quality control materials, well-characterized and validated targets, the optimal design of methodologies, with standardized assay steps in a technically validated pre-analytical phase that follows international guidelines. The assay must have acceptable values of trueness and precision that are determined using appropriate reference procedures and validated laboratories. The assay should also meet any regulations or accreditation requirements. Clinical processes must also be very carefully standardized with emphasis on international guidelines for the establishment of appropriate pre-analytical quality controls. (Dinnes et al.2022)

Accurate interpretation of the test results depends upon the appropriate use of decision thresholds. The overall clinical sensitivity and specificity of a biomarker combination may be inadequate except for very specific clinical settings, which imply the optimization of different testing strategies. The most basic validity of a marker only refers to its correlation with a clinical endpoint. This early phase is followed by evaluation of the utility of markers in clinical situations. Successful translation of this evidence to the clinical situation is further complicated by the fact that the medical laboratory is often a multispecialist environment. There are greater and more varied clinical needs for modern clinical pathology services, together with a rapidly evolving array of new molecular technologies. This translates into a greater need for multidisciplinary, integrated teams that can follow evolutions and bring all the key elements together. The added value of such groups will be better patient care at optimized costs.

## 5. Future Directions and Emerging Technologies

Future studies integrating three important components of translational research, i.e., diagnostic, prognostic, and treatment-response profiling on a large and frequent scale, will likely steer cancer research towards personalized and predictive molecular oncology. Major obstacles to accomplishing these goals are the relatedness of genes in the human genome, the confounding

influence of heterogeneity in the human gene sequence, and the lack of knowledge of how combinations of genetic and epigenetic events synergize cooperatively to drive oncogenesis. Recognizing the limitations of using single or very few biological replicates, researchers are developing new strategies and standards to leverage the typical increase in the dimensionality and complexity of cancer sample studies, prioritizing those technologies that have been proven to deliver biological validation and the highest increase in biological and medical information. (Kiran et al.2024)

Taking into consideration these technical, economic, and clinical challenges, researchers are developing various strategies to rapidly advance predictions of cancer prognosis, therapeutic response, and clinical outcome. These and other new approaches such as global profiling of microRNA, single nucleotide polymorphism genotyping, mutations in cancer-targeted genes in serum DNA, methylation of cancer genes, and a quantitative gene-expression assay using polymerase chain reaction applied to ductal lavage samples, urinary sediment DNA, serum mRNA, combined protein, as well as gene-expression microarray assays prior to or consecutively to repeated MRI or biopsy for the early detection of breast and other solid cancer types, can be envisioned to have the potential to facilitate more frequent, cost-effective, and patient-friendly approaches for early cancer detection and pre-symptomatic clinical management of cancer. (Labrie et al.2022)

The evolution in the field of molecular diagnostics can generate a revolution in the way we manage currently non-curable diseases since if we detect them at early stages when there are still therapeutic possibilities to avoid fatal outcomes.

**conclusion**

Overall, over the past few years, we have seen significant advances in the ability to detect causes of infectious and inheritable diseases. Particularly, the chances of developing highly accurate nucleotide sequencing tools provide great promise for the future. These tools are not yet ready for implementation in the diagnostic laboratory, but their continued development should provide new opportunities for understanding the genetic structure of infectious diseases. There are also many situations in clinical diagnostic laboratories in which the cost of nucleotide sequencing is essentially the same as that of other molecular techniques. As the efficiencies of gene detection increase, it is likely that the additional utility that comes from nucleotide sequencing will also increase.

While advances in technology are ongoing and most likely will produce fast and accurate results for pathogens and genetic traits in the near future, the challenge is to primarily develop the relevance of the information and its utility for both the patients and the physicians involved. When suitably defined, the association between a gene or genetic trait and its phenotype, both expressivity and penetrance, illuminates basic biological questions and institutions. Once the linkage can be used to enhance diagnosis, management, and treatment, its relevance is clear, but before these responses are established, individuals must be developed with very explicit phenotypes. Providing useful meaning to genes and phenotypes would be essential for human genetics to fulfill its promise for medical diagnostics, especially for cancer and pediatric diagnostic indications.

References:

Sethi, Paalki, et al. "Exploring advancements in early detection of Alzheimer's disease with molecular assays and animal models." Ageing Research Reviews (2024): 102411. [HTML]

Addissouky, T. A., Sayed, I. E. T. E., Ali, M. M. A., and Wang, Y. "Emerging biomarkers for precision diagnosis and personalized treatment of cystic fibrosis." Journal of Rare Diseases, 2024. springer.com

Johnson, Philip, et al. "Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma." Nature reviews Gastroenterology & hepatology 19.10 (2022): 670-681. liverpool.ac.uk

Islam, K. U. and Iqbal, J. "An update on molecular diagnostics for COVID-19." Frontiers in cellular and infection microbiology, 2020. frontiersin.org
Lopes, L. C., Santos, A., and Bueno, P. R. "An outlook on electrochemical approaches for molecular diagnostics assays and discussions on the limitations of miniaturized technologies for point-of-care …." Sensors and Actuators Reports, 2022. sciencedirect.com
Ren, Chongmin, et al. "Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications." Cancer and metastasis reviews (2024): 1-16. springer.com
Groft, S. C., Posada, M., and Taruscio, D. "Progress, challenges and global approaches to rare diseases." Acta paediatrica, 2021. researchgate.net
Kang, T., Lu, J., Yu, T., Long, Y., and Liu, G. "Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example." Biosensors and Bioelectronics, 2022. [HTML]
Udugama, Buddhisha, et al. "Diagnosing COVID-19: the disease and tools for detection." ACS nano 14.4 (2020): 3822-3835. acs.org
MacLean, Emily, et al. "Advances in molecular diagnosis of tuberculosis." Journal of clinical microbiology 58.10 (2020): 10-1128. asm.org
Crosby, David, et al. "Early detection of cancer." Science 375.6586 (2022): eaay9040. science.org
Tonry, C., Finn, S., Armstrong, J., and Pennington, S. R. "Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management." Clinical Proteomics, 2020. springer.com
Tsang, C. C., Teng, J. L. L., Lau, S. K. P., and Woo, P. C. Y. "Rapid genomic diagnosis of fungal infections in the age of next-generation sequencing." Journal of Fungi, 2021. mdpi.com
Dinnes, Jacqueline, et al. "Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection." Cochrane database of systematic reviews 7 (2022). cochranelibrary.com
Kiran, Neelakanta Sarvashiva, et al. "Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies." ACS Pharmacology & Translational Science 7.4 (2024): 967-990. acs.org
Labrie, Marilyne, et al. "Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer." Nature reviews Cancer 22.6 (2022): 323-339. nih.gov